{"id":281895,"date":"2010-02-05T08:41:31","date_gmt":"2010-02-05T13:41:31","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2010\/02\/05\/why-pharmas-patent-cliff-is-good-news-for-pharmacies\/"},"modified":"2010-02-05T08:41:31","modified_gmt":"2010-02-05T13:41:31","slug":"why-pharma%e2%80%99s-patent-cliff-is-good-news-for-pharmacies","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/281895","title":{"rendered":"Why Pharma\u2019s Patent Cliff Is Good News for Pharmacies"},"content":{"rendered":"<p><img decoding=\"async\" src=\"http:\/\/s.wsj.net\/media\/walgreen_C_20100114111138.jpg\" alt=\"Walgreen\" align=\"right\"\/>A bunch of the blockbuster drugs that carried the drug industry for the past decade are about to go off patent. As we&#8217;ve noted along with everybody else, that&#8217;s going to be tough for pharma companies. <\/p>\n<p>(See, for example, the news this week from <a href=\"http:\/\/blogs.wsj.com\/health\/2010\/02\/03\/pfizer-plans-to-cut-billions-in-annual-rd-spending\/\" >Pfizer<\/a> and <a href=\"http:\/\/blogs.wsj.com\/health\/2010\/02\/03\/bristol-meyers-squibb-to-freeze-salaries-in-2010\/\" >Bristol-Myers Squibb<\/a>, which over the next two years will face generic competition on the two biggest drugs in the world, Lipitor and Plavix.)<\/p>\n<p>Generic manufacturers are obvious beneficiaries here. But pharmacies will also profit. Although generic drugs are far cheaper than their branded equivalents, pharmacies make higher margins from generics. <\/p>\n<p>What&#8217;s more, the market may be undervaluing the gain CVS and Walgreen are likely to see from the wave of new generics, according to money managers quoted in a <a href=\"http:\/\/www.bloomberg.com\/apps\/news?pid=20601202&#038;sid=aQ9rfekrjaUo\" >Bloomberg News story<\/a> out today.<\/p>\n<p>The CFOs of both companies were, predictably, cautious about getting into the specifics of how much they&#8217;d benefit.<\/p>\n<p>&#8220;It will definitely help us, but to that magnitude, considering there are other things that play in, I would hesitate to give any guidance,&#8221; Walgreen&#8217;s CFO told Bloomberg. &#8220;There are lots of moving parts in this business and different people factor them in different ways.&#8221; <\/p>\n<p><em>Photo by <a href=\"http:\/\/flickr.com\/photos\/puroticorico\/2076663219\/\" >puroticorico<\/a> via Flickr<\/em><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~at\/rxFBE2uw8cdxAlUyjD4-GsN9FQI\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~at\/rxFBE2uw8cdxAlUyjD4-GsN9FQI\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~at\/rxFBE2uw8cdxAlUyjD4-GsN9FQI\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~at\/rxFBE2uw8cdxAlUyjD4-GsN9FQI\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=ZhDKL86qUcU:SKw3UAbO7cU:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=ZhDKL86qUcU:SKw3UAbO7cU:D7DqB2pKExk\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?i=ZhDKL86qUcU:SKw3UAbO7cU:D7DqB2pKExk\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=ZhDKL86qUcU:SKw3UAbO7cU:F7zBnMyn0Lo\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?i=ZhDKL86qUcU:SKw3UAbO7cU:F7zBnMyn0Lo\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=ZhDKL86qUcU:SKw3UAbO7cU:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?i=ZhDKL86qUcU:SKw3UAbO7cU:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=ZhDKL86qUcU:SKw3UAbO7cU:qj6IDK7rITs\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?d=qj6IDK7rITs\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/wsj\/health\/feed\/~4\/ZhDKL86qUcU\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A bunch of the blockbuster drugs that carried the drug industry for the past decade are about to go off patent. As we&#8217;ve noted along with everybody else, that&#8217;s going to be tough for pharma companies. (See, for example, the news this week from Pfizer and Bristol-Myers Squibb, which over the next two years will [&hellip;]<\/p>\n","protected":false},"author":650,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-281895","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/281895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/650"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=281895"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/281895\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=281895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=281895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=281895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}